Dantrolene low-volume - Eagle Pharmaceuticals
Alternative Names: Dantrolene; Dantrolene sodium; EA 111; EP-4104; RyanodexLatest Information Update: 28 Dec 2024
Price :
$50 *
At a glance
- Originator Lyotropic Therapeutics
- Developer Eagle Pharmaceuticals; NorthShore University HealthSystem; University of Pennsylvania
- Class Antidementias; Antipyretics; Antispastics; Antivirals; Furans; Hydantoins; Imidazolidines; Muscle relaxants; Neuroprotectants; Nitrophenols; Small molecules
- Mechanism of Action Ryanodine receptor calcium release channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Fever
- Phase II Chemically-induced disorders
- No development reported Alzheimer's disease; Chronic brain damage; COVID 2019 infections; Traumatic brain injuries
- Discontinued Wounds
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for preclinical development in Chronic-brain-damage in USA (IM)
- 28 May 2024 No recent reports of development identified for preclinical development in COVID-2019-infections in USA (Injection, Suspension)
- 28 Apr 2024 No recent reports of development identified for preclinical development in Traumatic-brain-injuries in USA